This article explores the targets that affect local CD8+ T-cell infiltration in tumors and subsequently affect patient prognosis (IL-1A, IL1RAP, IL18RAP, SIGIRR), which may also become a breakthrough in improving tumor treatment efficacy. This evidence concerns the gene IL1A and neoplasm.